Proven safety and patient tolerability profile1

Clinical trials have proven the safety of NeuroStar TMS Therapy in the treatment of patients with major depressive disorder and who have had an inadequate response to prior antidepressant medication.

Established safety profile and treatment adherence with less than 5% discontinuation rate with NeuroStar TMS Therapy due to adverse events.10

Treatment with NeuroStar TMS Therapy caused few side effects and was generally well tolerated by patients.1

  • The most common side effect reported during clinical trials was pain or discomfort at or near the treatment site10
  • Side effects are generally mild to moderate and do not occur for most patients after the first week of treatment10
  • Avoids the systemic side effects typically associated with antidepressant medications1,10
  • No adverse effect on cognition1,10

There is a low risk of seizure with TMS Therapy. The estimated risk of seizure under ordinary clinical use is approximately 1 in 30,000 treatments (0.003% of treatments) or 1 in 1000 patients (0.1% of patients).1

Patients should be carefully monitored for worsening symptoms, signs or symptoms of suicidal behavior and/or unusual behavior. Families and caregivers should also be aware of the need to observe patients and notify their treatment provider if symptoms worsen.1

NeuroStar TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head.

The mechanism of action behind NeuroStar TMS Therapy